Phase 1/2 Study of ADI-SS PEG 20,000mw in Patients With Advanced Melanoma
Phase of Trial: Phase I/II
Latest Information Update: 23 Nov 2017
At a glance
- Drugs Pegargiminase (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 30 Apr 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Apr 2010 Actual end date (Mar 2010) added as reported by ClinicalTrials.gov.